Kaiyuan Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kaiyuan Tang has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Sidi Chen
Department of Genetics, Yale University School of Medicine, New haven, CT, USA
9 shared publications - Chuanpeng Dong
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut
6 shared publications - Di Feng
Global Computational Biology and Data Science Department, Boehringer Ingelheim, Ridgefield, Connecticut
6 shared publications - Feifei Zhang
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut
6 shared publications - Hongyu Zhao
Department of Biostatistics, Yale School of Public Health, New Haven, USA
6 shared publications - James Cai
Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program, New Haven, Connecticut
6 shared publications
Latest Publications
- 4 November 2026
- Published by Springer Nature in Nature
In vivo CAR-T double knockout screen maps synergistic antitumour gene pairs
- 4 November 2026
- Published by Springer Nature in Nature
In vivo CAR-T double knockout screen maps synergistic antitumour gene pairs
- 13 July 2026
- Published by Springer Nature in Nature
- Vol. 656 (8126) , E2
Author Correction: OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours
- 13 July 2026
- Published by Springer Nature in Nature
- Vol. 656 (8126) , E2
Author Correction: OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours
- Top Cited Papers
- 25 February 2026
- Published by Springer Nature in Nature
- Vol. 652 (8110) , 740-751
OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours
Chimeric antigen receptor (CAR)-natural killer (NK) cell therapies hold promise for solid tumours but remain limited because of poor tumour infiltration, persistence and resistance in the tumour microenvironment1-4. Here, to identify gain-of-function targets that enhance CAR-NK cell efficacy, we performed an unbiased in vivo CRISPR activation screen followed by a barcoded targeted in vivo open reading frame screen in primary human CAR-NK cells. We identified and comprehensively validated OR7A10, a G protein-coupled receptor (GPCR), as the top candidate. Engineering CAR-NK cells with OR7A10 cDNA (a CRISPR-independent method with a simple manufacturing strategy) enhanced their proliferation, activation, degranulation, cytokine production, death ligand expression, chemokine receptor expression, cytotoxicity, persistence, metabolic fitness and tumour microenvironment resistance. Moreover, exhaustion in primary human NK cells derived from multiple peripheral blood and cord blood donors was reduced. OR7A10 gain-of-function CAR-NK cells displayed strong in vivo efficacy across multiple solid tumour models. For example, 100% complete response with long-term tumour control and survival benefit in an orthotopic breast cancer mouse model were achieved. These findings establish OR7A10-engineered CAR-NK cells as a highly potent and scalable off-the-shelf therapeutic for solid tumours.
- 25 February 2026
- Published by Springer Nature in Nature
- Vol. 652 (8110) , 740-751
Top Cited PapersOR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours
Chimeric antigen receptor (CAR)-natural killer (NK) cell therapies hold promise for solid tumours but remain limited because of poor tumour infiltration, persistence and resistance in the tumour microenvironment1-4. Here, to identify gain-of-function targets that enhance CAR-NK cell efficacy, we performed an unbiased in vivo CRISPR activation screen followed by a barcoded targeted in vivo open reading frame screen in primary human CAR-NK cells. We identified and comprehensively validated OR7A10, a G protein-coupled receptor (GPCR), as the top candidate. Engineering CAR-NK cells with OR7A10 cDNA (a CRISPR-independent method with a simple manufacturing strategy) enhanced their proliferation, activation, degranulation, cytokine production, death ligand expression, chemokine receptor expression, cytotoxicity, persistence, metabolic fitness and tumour microenvironment resistance. Moreover, exhaustion in primary human NK cells derived from multiple peripheral blood and cord blood donors was reduced. OR7A10 gain-of-function CAR-NK cells displayed strong in vivo efficacy across multiple solid tumour models. For example, 100% complete response with long-term tumour control and survival benefit in an orthotopic breast cancer mouse model were achieved. These findings establish OR7A10-engineered CAR-NK cells as a highly potent and scalable off-the-shelf therapeutic for solid tumours.
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from TCPGdb: A Comprehensive T-cell Perturbation Genomics Database for the Identification of Critical T-cell Regulators
Supplementary Figure S3. Characterization of the top 50 loss-of-function genes across CAR-T and T cell lymphoma datasets using TCPGdb.
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from TCPGdb: A Comprehensive T-cell Perturbation Genomics Database for the Identification of Critical T-cell Regulators
Supplementary Figure S3. Characterization of the top 50 loss-of-function genes across CAR-T and T cell lymphoma datasets using TCPGdb.
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from TCPGdb: A Comprehensive T-cell Perturbation Genomics Database for the Identification of Critical T-cell Regulators
Supplementary Figure S2. Summary of top genes and pathways ranked by T cell perturbation score (TPS) from CD4+ T cell screen data.
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from TCPGdb: A Comprehensive T-cell Perturbation Genomics Database for the Identification of Critical T-cell Regulators
Supplementary Figure S2. Summary of top genes and pathways ranked by T cell perturbation score (TPS) from CD4+ T cell screen data.
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Data from TCPGdb: A Comprehensive T-cell Perturbation Genomics Database for the Identification of Critical T-cell Regulators
Large parallel genetic screens have been used to identify targets and regulators that enhance T-cell antitumor capability and persistence in the tumor microenvironment. We hypothesized that by combining the pooled screen data from multiple independent genetic screens, we could provide a systematic, comprehensive, and robust analysis of the effect of gene perturbation on T cell–based immunotherapies. After collecting data from previously published T-cell screens, including CRISPR-based and open reading frame–based screens, through the Gene Expression Omnibus, we reprocessed the gene hits summary and conducted a pathway enrichment analysis. A T-cell screen perturbation score metric was employed to quantify the impact of a gene perturbation on T-cell function. Additionally, gene expression data (both bulk RNA level and single-cell RNA level) from autoimmune disease cohorts and patients with T cell–derived cancer were incorporated to gain further insight into gene perturbations that potentially augment T-cell proliferation. We integrated all data and analysis on 35 T-cell screens into our state-of-the-art T-cell perturbation genomics database (TCPGdb), which is accessible through our web server (http://tcpgdb.sidichenlab.org/) and allows users to interactively explore the impact of query genes on T-cell function.
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from TCPGdb: A Comprehensive T-cell Perturbation Genomics Database for the Identification of Critical T-cell Regulators
Large parallel genetic screens have been used to identify targets and regulators that enhance T-cell antitumor capability and persistence in the tumor microenvironment. We hypothesized that by combining the pooled screen data from multiple independent genetic screens, we could provide a systematic, comprehensive, and robust analysis of the effect of gene perturbation on T cell–based immunotherapies. After collecting data from previously published T-cell screens, including CRISPR-based and open reading frame–based screens, through the Gene Expression Omnibus, we reprocessed the gene hits summary and conducted a pathway enrichment analysis. A T-cell screen perturbation score metric was employed to quantify the impact of a gene perturbation on T-cell function. Additionally, gene expression data (both bulk RNA level and single-cell RNA level) from autoimmune disease cohorts and patients with T cell–derived cancer were incorporated to gain further insight into gene perturbations that potentially augment T-cell proliferation. We integrated all data and analysis on 35 T-cell screens into our state-of-the-art T-cell perturbation genomics database (TCPGdb), which is accessible through our web server (http://tcpgdb.sidichenlab.org/) and allows users to interactively explore the impact of query genes on T-cell function.
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from TCPGdb: A Comprehensive T-cell Perturbation Genomics Database for the Identification of Critical T-cell Regulators
Supplementary Figure S1. Correlation of T cell screen data sets and TPS scores.
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from TCPGdb: A Comprehensive T-cell Perturbation Genomics Database for the Identification of Critical T-cell Regulators
Supplementary Figure S1. Correlation of T cell screen data sets and TPS scores.
- 21 November 2025
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (2) , 219-227
TCPGdb: A Comprehensive T-cell Perturbation Genomics Database for the Identification of Critical T-cell Regulators
Large parallel genetic screens have been used to identify targets and regulators that enhance T-cell antitumor capability and persistence in the tumor microenvironment. We hypothesized that by combining the pooled screen data from multiple independent genetic screens, we could provide a systematic, comprehensive, and robust analysis of the effect of gene perturbation on T cell–based immunotherapies. After collecting data from previously published T-cell screens, including CRISPR-based and open reading frame–based screens, through the Gene Expression Omnibus, we reprocessed the gene hits summary and conducted a pathway enrichment analysis. A T-cell screen perturbation score metric was employed to quantify the impact of a gene perturbation on T-cell function. Additionally, gene expression data (both bulk RNA level and single-cell RNA level) from autoimmune disease cohorts and patients with T cell–derived cancer were incorporated to gain further insight into gene perturbations that potentially augment T-cell proliferation. We integrated all data and analysis on 35 T-cell screens into our state-of-the-art T-cell perturbation genomics database (TCPGdb), which is accessible through our web server (http://tcpgdb.sidichenlab.org/) and allows users to interactively explore the impact of query genes on T-cell function.
- 21 November 2025
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (2) , 219-227
TCPGdb: A Comprehensive T-cell Perturbation Genomics Database for the Identification of Critical T-cell Regulators
Large parallel genetic screens have been used to identify targets and regulators that enhance T-cell antitumor capability and persistence in the tumor microenvironment. We hypothesized that by combining the pooled screen data from multiple independent genetic screens, we could provide a systematic, comprehensive, and robust analysis of the effect of gene perturbation on T cell–based immunotherapies. After collecting data from previously published T-cell screens, including CRISPR-based and open reading frame–based screens, through the Gene Expression Omnibus, we reprocessed the gene hits summary and conducted a pathway enrichment analysis. A T-cell screen perturbation score metric was employed to quantify the impact of a gene perturbation on T-cell function. Additionally, gene expression data (both bulk RNA level and single-cell RNA level) from autoimmune disease cohorts and patients with T cell–derived cancer were incorporated to gain further insight into gene perturbations that potentially augment T-cell proliferation. We integrated all data and analysis on 35 T-cell screens into our state-of-the-art T-cell perturbation genomics database (TCPGdb), which is accessible through our web server (http://tcpgdb.sidichenlab.org/) and allows users to interactively explore the impact of query genes on T-cell function.